Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells

BMC Biology

Volumn 8, Issue , 2010, Pages

  Rico Bautista, Elizabeth ^a   Yang, Chih Cheng ^a   Lu, Lifang ^a,b   Roth, Gregory P ^a   Wolf, Dieter A ^a  

^a BURNHAM INSTITUTE   (United States)

^b GE Healthcare   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CDKN1B PROTEIN, HUMAN; S PHASE KINASE ASSOCIATED PROTEIN; SIGNAL PEPTIDE;

ARTICLE; CARCINOMA; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; EVALUATION; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; HIGH THROUGHPUT SCREENING; HUMAN; ISOLATION AND PURIFICATION; MALE; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; PROTEIN PROCESSING; TUMOR CELL CULTURE; UPREGULATION; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; CARCINOMA; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; S-PHASE KINASE-ASSOCIATED PROTEINS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 78650383624     PISSN: None     EISSN: 17417007     Source Type: Journal    
DOI: 10.1186/1741-7007-8-153     Document Type: Article

References (56)

1. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008, 8:253-267. 10.1038/nrc2347, 18354415.
2. De Marzo AM, Meeker AK, Epstein JI, Coffey DS. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol 1998, 153:911-919. 1853003, 9736039.
3. Cheville JC, Lloyd RV, Sebo TJ, Cheng L, Erickson L, Bostwick DG, Lohse CM, Wollan P. Expression of p27kip1 in prostatic adenocarcinoma. Mod Pathol 1998, 11:324-328.
4. Cote RJ, Shi Y, Groshen S, Feng AC, Cordon-Cardo C, Skinner D, Lieskovosky G. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998, 90:916-920. 10.1093/jnci/90.12.916, 9637141.
5. Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 1998, 12:941-953. 10.1210/me.12.7.941, 9658399.
6. Chen J, Willingham T, Shuford M, Nisen PD. Tumor Suppression and Inhibition of Aneuploid Cell Accumulation in Human Brain Tumor Cells by Ectopic Overexpression of the Cyclin-dependent Kinase Inhibitor p27KIP1. J Clin Invest 1996, 97:1983-1988. 10.1172/JCI118631, 507269, 8621784.
7. Craig C, Wersto R, Kim M, Ohri E, Li Z, Katayose D, Lee SJ, Trepel J, Cowan K, Seth P. A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 1997, 14:2283-2289. 10.1038/sj.onc.1201064, 9178904.
8. Hengst L, Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. Science 1996, 271:1861-1864. 10.1126/science.271.5257.1861, 8596954.
9. Cheng M, Sexl V, Sherr CJ, Roussel MF. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci USA 1998, 95:1091-1096. 10.1073/pnas.95.3.1091, 18683, 9448290.
10. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, Fusco A, Santoro M. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002, 8:1136-1144. 10.1038/nm762, 12244303.
11. Chu I, Sun J, Arnaout A, Kahn H, Hanna W, Narod S, Sun P, Tan CK, Hengst L, Slingerland J. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 2007, 128:281-294. 10.1016/j.cell.2006.11.049, 1961623, 17254967.
12. Grimmler M, Wang Y, Mund T, Cilensek Z, Keidel EM, Waddell MB, Jakel H, Kullmann M, Kriwacki RW, Hengst L. Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell 2007, 128:269-280. 10.1016/j.cell.2006.11.047, 17254966.
13. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999, 9:661-664. 10.1016/S0960-9822(99)80290-5, 10375532.
14. Alessandrini A, Chiaur DS, Pagano M. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 1997, 11:342-345. 10.1038/sj.leu.2400581, 9067571.
15. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilcyznski S, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 1995, 55:2266-2269.
16. Ponce-Castaneda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J, Massague J, et al. p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995, 55:1211-1214.
17. Pietenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, Friedman C, Trask BJ, Roberts JM, Kinzler KW, Rowley JD, et al. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 1995, 55:1206-1210.
18. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J, Scher HI. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998, 90:1284-1291. 10.1093/jnci/90.17.1284, 9731735.
19. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997, 3:227-230. 10.1038/nm0297-227, 9018244.
20. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269:682-685. 10.1126/science.7624798, 7624798.
21. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998, 67:425-479. 10.1146/annurev.biochem.67.1.425, 9759494.
22. Carrano AC, Eytan E, Hershko A, Pagano M. Skp2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nature Cell Biol 1999, 1:193-199. 10.1038/12013, 10559916.
23. Hara T, Kamura T, Kotoshiba S, Takahashi H, Fujiwara K, Onoyama I, Shirakawa M, Mizushima N, Nakayama KI. Role of the UBL-UBA Protein KPC2 in Degradation of p27 at G1 Phase of the Cell Cycle. Mol Cell Biol 2005, 25:9292-9303. 10.1128/MCB.25.21.9292-9303.2005, 1265808, 16227581.
24. Hattori T, Isobe T, Abe K, Kikuchi H, Kitagawa K, Oda T, Uchida C, Kitagawa M. Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1. Cancer Res 2007, 67:10789-10795. 10.1158/0008-5472.CAN-07-2033, 18006823.
25. Kamura T, Hara T, Matsumoto M, Ishida N, Okumura F, Hatakeyama S, Yoshida M, Nakayama K, Nakayama KI. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol 2004, 6:1229-1235. Epub 2004 Nov 1227, 10.1038/ncb1194, 15531880.
26. Nakayama K, Nagahama H, Minamishima YA, Miyake S, Ishida N, Hatakeyama S, Kitagawa M, Iemura S, Natsume T, Nakayama KI. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell 2004, 6:661-672. 10.1016/S1534-5807(04)00131-5, 15130491.
27. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Krek W. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 2001, 98:5043-5048. 10.1073/pnas.081474898, 33160, 11309491.
28. Kudo Y, Kitajima S, Sato S, Miyauchi M, Ogawa I, Takata T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 2001, 61:7044-7047.
29. Yang G, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler TM, Thompson TC, Harper JW. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002, 8:3419-3426.
30. Hershko D, Bornstein G, Ben-Izhak O, Carrano A, Pagano M, Krausz MM, Hershko A. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 2001, 91:1745-1751. 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO;2-H, 11335900.
31. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000, 183:10-17. 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I, 10699961.
32. Shim EH, Johnson L, Noh HL, Kim YJ, Sun H, Zeiss C, Zhang H. Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res 2003, 63:1583-1588.
33. Lu L, Schulz H, Wolf DA. The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. BMC Cell Biol 2002, 3:22. 10.1186/1471-2121-3-22, 122093, 12188931.
34. Sumimoto H, Yamagata S, Shimizu A, Miyoshi H, Mizuguchi H, Hayakawa T, Miyagishi M, Taira K, Kawakami Y. Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther 2004,
35. Cardozo T, Pagano M. Wrenches in the works: drug discovery targeting the SCF ubiquitin ligase and APC/C complexes. BMC Biochem 2007, 8(Suppl 1):S9. 10.1186/1471-2091-8-S1-S9, 2106342, 18047746.
36. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA. The LNCaP cell line--a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980, 37:115-132.
37. Zhang JH, Chung TD, Oldenburg KR. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 1999, 4:67-73. 10.1177/108705719900400206, 10838414.
38. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R. Statistical practice in high-throughput screening data analysis. Nat Biotechnol 2006, 24:167-175. 10.1038/nbt1186, 16465162.
39. Duijn P, Trapman J. PI3K/Akt signaling regulates p27kip1expression via Skp2 in PC3 and DU145 prostate cancer cells, but is not a major factor in p27kip1 regulation in LNCaP and PC346 cells. The Prostate 2006, 66:749-760. 10.1002/pros.20398, 16425184.
40. Zhang GJ, Kaelin WG. Bioluminescent imaging of ubiquitin ligase activity: measuring Cdk2 activity in vivo through changes in p27 turnover. Methods Enzymol 2005, 399:530-549. 10.1016/S0076-6879(05)99036-8, 16338380.
41. Li X, Guan B, Maghami S, Bieberich CJ. NKX3.1 is regulated by protein kinase CK2 in prostate tumor cells. Mol Cell Biol 2006, 26:3008-3017. 10.1128/MCB.26.8.3008-3017.2006, 1446956, 16581776.
42. Guan B, Pungaliya P, Li X, Uquillas C, Mutton LN, Rubin EH, Bieberich CJ. Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1. J Biol Chem 2008, 283:4834-4840. 10.1074/jbc.M708630200, 18077445.
43. Zhang GJ, Safran M, Wei W, Sorensen E, Lassota P, Zhelev N, Neuberg DS, Shapiro G, Kaelin WG. Bioluminescent imaging of Cdk2 inhibition in vivo. Nat Med 2004, 10:643-648. 10.1038/nm1047, 15122251.
44. Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, Fedele G, Baek WK, Wang S, Ellwood-Yen K, Wu H, Sawyers CL, Signoretti S, Hahn WC, Loda M, Sellers WR. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 2008, 14:146-155. 10.1016/j.ccr.2008.06.002, 2583442, 18691549.
45. Nickeleit I, Zender S, Sasse F, Geffers R, Brandes G, Sorensen I, Steinmetz H, Kubicka S, Carlomagno T, Menche D, Gutgemann I, Buer J, Gossler A, Manns MP, Kalesse M, Frank R, Malek NP. Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 2008, 14:23-35. 10.1016/j.ccr.2008.05.016, 18598941.
46. Bornstein G, Bloom J, Sitry-Shevah D, Nakayama K, Pagano M, Hershko A. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem 2003, 278:25752-25757. 10.1074/jbc.M301774200, 12730199.
47. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999, 13:1181-1189. 10.1101/gad.13.9.1181, 316946, 10323868.
48. Nickeleit I, Zender S, Kossatz U, Malek NP. p27kip1: a target for tumor therapies?. Cell Div 2007, 2:13. 10.1186/1747-1028-2-13, 1872022, 17488529.
49. Soeiro I, Mohamedali A, Romanska HM, Lea NC, Child ES, Glassford J, Orr SJ, Roberts C, Naresh KN, Lalani E-N, Mann DJ, Watson RJ, Thomas NSB, Lam EW-F. p27Kip1 and p130 Cooperate To Regulate Hematopoietic Cell Proliferation In Vivo. Mol Cell Biol 2006, 26:6170-6184. 10.1128/MCB.02182-05, 1592787, 16880527.
50. Coats S, Whyte P, Fero ML, Lacy S, Chung G, Randel E, Firpo E, Roberts JM. A new pathway for mitogen-dependent Cdk2 regulation uncovered in p27Kip1-deficient cells. 1999, 9:163-173.
51. Macpherson I, Montagnier L. Agar Suspension Culture for the Selective Assay of Cells Transformed by Polyoma Virus. Virology 1964, 23:291-294. 10.1016/0042-6822(64)90301-0, 14187925.
52. Freedman VH, Shin SI. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 1974, 3:355-359. 10.1016/0092-8674(74)90050-6, 4442124.
53. Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, Cordon-Cardo C, Teruya-Feldstein J, Pandolfi PP. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010, 464:374-379. 10.1038/nature08815, 2928066, 20237562.
54. Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, Al-Kuraya KS. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Res 2008, 68:3379-3388. 10.1158/0008-5472.CAN-07-6109, 18451165.
55. Wolf DA, Hermeking H, Albert T, Herzinger T, Kind P, Eick D. A complex between E2F and the pRb-related protein p130 is specifically targeted by the simian virus 40 large T antigen during cell transformation. Oncogene 1995, 10:2067-2078.
56. Liu S, Yamauchi H. p27-Associated G1 arrest induced by hinokitiol in human malignant melanoma cells is mediated via down-regulation of pRb, Skp2 ubiquitin ligase, and impairment of Cdk2 function. Cancer Lett 2009, 286:240-249. 10.1016/j.canlet.2009.05.038, 19631451.